FORM 6-K/A

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934


For period ending June 06, 2008

 

GlaxoSmithKline plc
(Name of registrant)

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


Form 20-F x Form 40-F
 --


Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x
  --

 
 

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 

I give below details of an increase in interests in Ordinary shares at a price of £10.73 per share and Ordinary share ADRs at a price of $43.32 per ADR in GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned persons, following the re-investment of the dividend paid to shareholders on 10 April 2008.

 

 

Ordinary shares

ADRs

Dr M M Slaoui

28.86

  

Mrs C E Bruck Slaoui

16.49

  

Mr EJ Gray

29.47

  

Mr D Learmouth

27.80

  

Mr W C Louv

  

14.19

Mr S M Werner

  

14.47

The Company and the above named persons were advised of this information on 18 April 2008.
 

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell
Company Secretary
 
18 April 2008



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 

                                                             GlaxoSmithKline plc
                                                                    (Registrant)

Date: June 06, 2008

                                                                                                        By: VICTORIA WHYTE
                                                                                                                                                                ------------------
                                                              Victoria Whyte
                                                 Authorised Signatory for and on
                                                   behalf of GlaxoSmithKline plc